CVRx®Barostim™ Heart Failure System Gains MR-Conditional Labeling Approval
CVRx, Inc., developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. FDA approval for magnetic resonance (MR) conditional labeling for its Barostim System.Heart FailureHeart failure is a chronic, progressive condition in...
Latest News
Japanese PMDA Approval for BioFreedom™ Ultra and US FDA Approval for BioFreedom™
Biosensors International Group, Ltd. has announced the Japanese PMDA Approval for BioFreedom™...
read the full article >Myopia in Childhood: Screens to Blame
Cases of Myopia (near-sightedness) have doubled since the 1960s and will double again by 2050...
read the full article >
Cardiology
Study Shows Promise for Next-Generation Cardiac Ablation Tech
Argá Medtech’s next-generation non-thermal cardiac ablation system shows promise in improving...
read the full article >
Approvals / Clearance
Clinical Studies / Trials
Archimedes Effective in Guiding Sampling of Cancerous Peripheral Lung Lesions
A newly published global multicenter study demonstrates the effectiveness of the Broncus Medical,...
read the full article >Tibial Neuromodulation for OAB: First Patient Implants
Medtronic plc says the first patient implants in the TITAN 2 pivotal study will evaluate the safety...
read the full article >